Glenmark Pharmaceuticals has reported a net profit of Rs 458 crore in its fourth quarter results announced on May 11. Glenn Saldanha, managing director and CEO of Glenmark Pharmaceuticals, in an interview with CNBC-TV18's Udayan Mukherjee and Mitali Mukherjee, said that its business in India is growing at 23-24%, while its business in US is expected to grow 25% in FY12.
Glenmark Pharma FY11 cons net profit at Rs 458 crore Below is a verbatim transcript of his interview. Also watch the accompanying video. Q: Your sales guidance has gone down well but for a lot of people the margin guidance seems a bit tepid despite taking into account the accounting changes that you are going to carry into next year. A: The margin guidance, we have guided to about 23% EBITDA margin and that is on account of certain higher R&D expenses and this is on the base business alone. So, the base business will clock about 23%. Over and above that whatever milestones and payments we get towards licensing will add to that. So all in all we think that is a reasonable guidance. Q: Tell us about the sales growth guidance of 20-25%, can you spilt that up between what you are expecting in the US versus IndiaDiscover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
